Almstead Neil Gregory

Almstead Neil Gregory, chief technical operations officer at PTC Therapeutics (PTCT), has been a consistent seller of company stock over the past several weeks, with Form 4 filings showing a clear disposition pattern. Across his 89 total trades, all concentrated in PTCT, he has recorded approximately $25.97 million in open-market sales with zero corresponding purchases, a bias that has intensified recently. The most active stretch came in early July 2026, when he executed multiple same-day sale-and-exercise combinations—for instance, on July 7 he sold shares worth roughly $830,718, $1,011,182, and $344,844 while simultaneously exercising options valued at about $970,244. Similar paired transactions occurred on July 6, with sales totaling over $1.9 million alongside option exercises near $847,600, and on July 9, when a $222,376 sale accompanied a $114,674 exercise. The pattern is mechanical rather than opportunistic: each sale is paired with an option exercise (code M), indicating that Gregory is converting vested awards into cash rather than making discretionary open-market disposals. The sales themselves are coded "S" (open-market), but they consistently follow exercises, and the dollar values are closely matched—suggesting a sell-to-cover or liquidity-driven approach. This is evident in late June as well, with June 25 transactions showing $980,763 and $726,585 in sales against a $756,627 exercise, and June 26 sales of $658,036 and $35,114 tied to exercises of $294,055 and $15,697. Notably, there are no purchases (code P) in the recent window, and the absence of any acquisition value across his entire filing history underscores that all share accumulation has come through compensation, not conviction buying. The recent 16 transactions, all sales or exercises, reinforce a steady monetization of equity awards rather than a reaction to price movements. While the total dollar volume is substantial, the structure—option exercises immediately followed by sales of similar magnitude—points to routine portfolio management by a senior officer. Investors monitoring insider activity would note the lack of open-market buying as a neutral signal, but the sheer frequency and size of the dispositions, concentrated in a single ticker over a two-week period, warrant attention as part of a broader insider sentiment picture for PTCT.